Literature DB >> 12776439

Understanding asthma pathophysiology.

Philip Fireman1.   

Abstract

Asthma is best described as a chronic disease that involves inflammation of the pulmonary airways and bronchial hyperresponsiveness that results in the clinical expression of a lower airway obstruction that usually is reversible. Physiologically, bronchial hyperresponsiveness is documented by decreased bronchial airflow after bronchoprovocation with methacholine or histamine. Other triggers that provoke airway obstruction include cold air, exercise, viral upper respiratory infection, cigarette smoke, and respiratory allergens. Bronchial provocation with allergen induces a prompt early phase immunoglobulin E (IgE)-mediated decrease in bronchial airflow (forced expiratory volume in 1 second) followed in many patients by a late-phase IgE-mediated reaction with a decrease in bronchial airflow for 4-8 hours. The gross pathology of asthmatic airways displays lung hyperinflation, smooth muscle hypertrophy, lamina reticularis thickening, mucosal edema, epithelial cell sloughing, cilia cell disruption, and mucus gland hypersecretion. Microscopically, asthma is characterized by the presence of increased numbers of eosinophils, neutrophils, lymphocytes, and plasma cells in the bronchial tissues, bronchial secretions, and mucus. Initially, there is recruitment of leukocytes from the bloodstream to the airway by activated CD4 T-lymphocytes. The activated T-lymphocytes also direct the release of inflammatory mediators from eosinophils, mast cells, and lymphocytes. In addition, the subclass 2 helper T-lymphocytes subset of activated T-lymphocytes produces interleukin (IL)-4, IL-5, and IL-13. IL-4 in conjunction with IL-13 signals the switch from IgM to IgE antibodies. The cross-linkage of two IgE molecules by allergen causes mast cells to degranulate, releasing histamine, leukotrienes, and other mediators that perpetuate the airway inflammation. IL-5 activates the recruitment and activation of eosinophils. The activated mast cells and eosinophils also generate their cytokines that help to perpetuate the inflammation. Regardless of the triggers of asthma, the repeated cycles of inflammation in the lungs with injury to the pulmonary tissues followed by repair may produce long-term structural changes ("remodeling") of the airways. This review will discuss in greater detail the relationships of inflammation and airway hyperresponsiveness to the pathophysiology of asthma.

Entities:  

Mesh:

Year:  2003        PMID: 12776439

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  39 in total

1.  Modulatory role for retinoid-related orphan receptor alpha in allergen-induced lung inflammation.

Authors:  Maisa Jaradat; Cliona Stapleton; Stephen L Tilley; Darlene Dixon; Christopher J Erikson; Joshua G McCaskill; Hong Soon Kang; Martin Angers; Grace Liao; Jennifer Collins; Sherry Grissom; Anton M Jetten
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

2.  The extract of Cordyceps sinensis inhibited airway inflammation by blocking NF-κB activity.

Authors:  Ya-Ling Chiou; Ching-Yuang Lin
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 3.  Biological therapies for eosinophilic gastrointestinal diseases.

Authors:  Joshua B Wechsler; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2018-05-31       Impact factor: 10.793

4.  Modification of Traffic-related Respiratory Response by Asthma Control in a Population of Car Commuters.

Authors:  Maria C Mirabelli; Rachel Golan; Roby Greenwald; Amit U Raysoni; Fernando Holguin; Priya Kewada; Andrea Winquist; W Dana Flanders; Jeremy A Sarnat
Journal:  Epidemiology       Date:  2015-07       Impact factor: 4.822

5.  Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice.

Authors:  Umesh C S Yadav; Amarjit S Naura; Leopoldo Aguilera-Aguirre; Kota V Ramana; Istvan Boldogh; Sanjiv Sur; Hamid A Boulares; Satish K Srivastava
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

6.  Work-related asthma among adults with current asthma in 33 states and DC: evidence from the Asthma Call-Back Survey, 2006-2007.

Authors:  Gretchen E Knoeller; Jacek M Mazurek; Jeanne E Moorman
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

7.  Editorial: leukocyte-targeting toxins as therapeutics in allergic asthma.

Authors:  Namit Sharma; Andrew W B Craig
Journal:  J Leukoc Biol       Date:  2015-03       Impact factor: 4.962

8.  Serum perfluoroalkyl substances and lung function in adolescents exposed to the World Trade Center disaster.

Authors:  Abigail Gaylord; Kenneth I Berger; Mrudula Naidu; Teresa M Attina; Joseph Gilbert; Tony T Koshy; Xiaoxia Han; Michael Marmor; Yongzhao Shao; Robert Giusti; Roberta M Goldring; Kurunthachalam Kannan; Leonardo Trasande
Journal:  Environ Res       Date:  2019-02-16       Impact factor: 6.498

9.  The effect of Ginkgo Biloba extract on the expression of PKCalpha in the inflammatory cells and the level of IL-5 in induced sputum of asthmatic patients.

Authors:  Yijun Tang; Yongjian Xu; Shengdao Xiong; Wang Ni; Shixin Chen; Baoan Gao; Tao Ye; Yong Cao; Chunling Du
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

10.  Bronchodilator response in patients with persistent allergic asthma could not predict airway hyperresponsiveness.

Authors:  Bojana B Petanjek; Sanja P Grle; Dubravka Pelicaric; Dubravka Vrankovic
Journal:  Allergy Asthma Clin Immunol       Date:  2007-12-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.